239 related articles for article (PubMed ID: 19074173)
1. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis.
Bonaci-Nikolic B; Jeremic I; Andrejevic S; Sefik-Bukilica M; Stojsavljevic N; Drulovic J
Lupus; 2009 Jan; 18(1):78-80. PubMed ID: 19074173
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis.
Bahri DM; Khiari H; Essouri A; Laadhar L; Zaraa I; Mrabet A; Meddeb N; Sellami S
Fundam Clin Pharmacol; 2012 Apr; 26(2):210-1. PubMed ID: 21323997
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy.
Sladkova V; Mares J; Lubenova B; Hlustik P; Kanovsky P
Neuro Endocrinol Lett; 2011; 32(1):4-6. PubMed ID: 21407162
[TBL] [Abstract][Full Text] [Related]
4. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus following HPV immunization or infection?
Soldevilla HF; Briones SF; Navarra SV
Lupus; 2012 Feb; 21(2):158-61. PubMed ID: 22235047
[TBL] [Abstract][Full Text] [Related]
6. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient.
Gono T; Matsuda M; Shimojima Y; Kaneko K; Murata H; Ikeda S
J Clin Neurosci; 2007 Oct; 14(10):997-1000. PubMed ID: 17669654
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
8. The use of interferon beta in relapsing-remitting multiple sclerosis.
Etheridge LJ; Beverley DW; Ferrie C; McManus E
Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
[TBL] [Abstract][Full Text] [Related]
9. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
10. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
[TBL] [Abstract][Full Text] [Related]
11. [Severe systemic lupus erythematosus induced by isoniazide].
Rakotoson JL; Randriamanana D; Rakotomizao JR; Andrianasolo R; Rakotoarivelo R; Andrianarisoa AC
Rev Pneumol Clin; 2009 Dec; 65(6):361-4. PubMed ID: 19995658
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
Martínez-Cáceres EM; Río J; Barrau M; Durán I; Borrás C; Tintoré M; Montalban X
Ann Neurol; 1998 Oct; 44(4):682-5. PubMed ID: 9778268
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
[TBL] [Abstract][Full Text] [Related]
14. Cotton wool spots associated with interferon beta-1 alpha therapy.
Longmuir R; Lee AG; Rouleau J
Semin Ophthalmol; 2007; 22(1):49-53. PubMed ID: 17366120
[TBL] [Abstract][Full Text] [Related]
15. Drug induced systemic lupus erythematosus due to ophthalmic timolol.
Zamber RW; Starkebaum G; Rubin RL; Martens HF; Wener MH
J Rheumatol; 1992 Jun; 19(6):977-9. PubMed ID: 1404139
[TBL] [Abstract][Full Text] [Related]
16. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
17. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?
Hügle T; Gratzl S; Daikeler T; Frey D; Tyndall A; Walker UA
Ann Rheum Dis; 2009 Jan; 68(1):47-50. PubMed ID: 18203763
[TBL] [Abstract][Full Text] [Related]
18. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
19. Interferon beta-1a overdose in a multiple sclerosis patient.
Falcone NP; Nappo A; Neuteboom B
Ann Pharmacother; 2005 Nov; 39(11):1950-2. PubMed ID: 16204396
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced lupus erythematosus.
Vedove CD; Del Giglio M; Schena D; Girolomoni G
Arch Dermatol Res; 2009 Jan; 301(1):99-105. PubMed ID: 18797892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
